Thermo Fisher Scientific Inc. announced that Stephen Williamson, the Senior Vice President and Chief Financial Officer (CFO), will retire on March 31, 2026. The Board of Directors has approved the appointment of James R. Meyer, currently Vice President of Financial Operations, to succeed Williamson as CFO starting March 1, 2026.
James R. Meyer has been with Thermo Fisher since July 2009, holding various finance positions of increasing responsibility, including Vice President of Finance for Customer Channels from April 2020 to December 2022. He has been in his current role since January 2023 and previously worked at PricewaterhouseCoopers.
linkJul 23, 2025 16:16:06
Thermo Fisher Scientific announced its financial results for the second quarter of 2025, reporting revenue of $10.85 billion, a 3% increase from the previous year. GAAP diluted earnings per share (EPS) rose to $4.28, up 6% year-over-year, while adjusted EPS was reported at $5.36. The company highlighted its operational performance, driven by a strong growth strategy and the launch of innovative products designed to enhance scientific research and drug development. Additionally, Thermo Fisher expanded its strategic partnership with Sanofi to acquire a sterile fill-finish site in New Jersey, which is expected to increase U.S. capacity for pharmaceutical production.
In terms of profitability, GAAP operating income for the quarter was $1.83 billion, with an operating margin of 16.9%. The adjusted operating income was $2.38 billion, resulting in an adjusted operating margin of 21.9%. The company plans to provide updated financial guidance for 2025 during its earnings conference call. Thermo Fisher Scientific emphasized its commitment to enabling customer success and adapting to market conditions through its operational strategies.
linkJul 23, 2025 06:03:44
Thermo Fisher Scientific Inc. announced its financial results for the first quarter of 2025, reporting a revenue of $10.36 billion, a slight increase from $10.34 billion in the same quarter of 2024. The company’s diluted earnings per share (EPS) rose 15% to $3.98, while adjusted EPS grew 1% to $5.15. The results reflect the company’s strong financial performance amidst a challenging macroeconomic environment, supported by new product launches and strategic partnerships aimed at enhancing productivity and innovation in the life sciences sector.
In addition to the revenue growth, Thermo Fisher executed its capital deployment strategy by agreeing to acquire Solventum’s Purification & Filtration Business for $4.1 billion in cash, repurchasing $2.0 billion of its own stock, and increasing its dividend by 10%. The company also highlighted advancements in its product offerings, including innovative systems for semiconductor analysis and precision medicine. The financial performance and strategic initiatives may influence investor sentiment and stock price movements.
linkApr 23, 2025 06:04:04
Thermo Fisher Scientific reported a fourth quarter revenue increase of 5%, reaching $11.40 billion, along with a 14% rise in GAAP diluted earnings per share (EPS) to $4.78. The company also showed positive growth in adjusted EPS, which grew 8% to $6.10. Throughout the year, Thermo Fisher continued to innovate by launching several new products and strengthening its market position, which contributed to a solid performance in the fourth quarter. Additionally, the company returned $4.6 billion to shareholders through stock buybacks and dividends.
However, the full year revenue remained flat at $42.88 billion compared to the previous year, with organic revenue growth reported as stagnant. While GAAP diluted EPS increased by 7% to $16.53, adjusted EPS saw only a 1% rise to $21.86. The adjusted operating income for the full year also declined slightly from $9.81 billion in 2023 to $9.71 billion in 2024, indicating some challenges in sustaining growth momentum over the year.
linkJan 30, 2025 06:03:21
Thermo Fisher Scientific announced strong financial results for the third quarter of 2024, achieving a revenue of $10.60 billion and an adjusted earnings per share (EPS) of $5.28. The company introduced innovative products aimed at enhancing life sciences research and advanced materials development, which reflects their commitment to growth and customer partnership. They also expanded their facilities to improve services for pharmaceutical and biotech clients, indicating a positive trajectory in their operational capabilities and customer engagement.
Despite the positive revenue growth, Thermo Fisher experienced a slight decline in both GAAP diluted EPS and adjusted EPS compared to the same quarter last year, indicating some challenges. The operating income also decreased slightly, and the operating margin showed a small dip. However, the company raised its full-year adjusted EPS guidance, suggesting confidence in achieving better results moving forward. Overall, while there are some areas of concern, the company's strategic initiatives and strong revenue performance highlight a generally positive outlook.
linkOct 23, 2024 06:03:27
Thermo Fisher Scientific announced its Q2 2024 results, showing a revenue of $10.54 billion, despite a slight decline from last year. Earnings per share rose 15% to $4.04. The company launched innovative products and expanded facilities to enhance customer support. Additionally, it raised its full-year revenue and earnings guidance, indicating confidence in future growth. However, organic revenue and core growth were flat, highlighting some challenges ahead.
linkJul 24, 2024 06:03:11
Thermo Fisher Scientific reports positive Q1 results with $10.34 billion revenue, 4% increase in GAAP EPS, and 2% increase in adjusted EPS. The company launched innovative products and expanded services, showing strong commercial execution. Despite a 3% revenue decline, Thermo Fisher raises its 2024 revenue and EPS guidance. GAAP operating income and margin improved. The company's focus on growth strategy and PPI Business System is driving success, aiming to create value for stakeholders and build a brighter future.
linkApr 24, 2024 06:03:01
Thermo Fisher Scientific reported a 5% decline in Q4 2023 revenue, with a 4% drop in core organic revenue growth. However, GAAP diluted EPS increased by 5%. The company highlighted advancements in its growth strategy, product launches, and CSR initiatives. It also completed strategic acquisitions and returned $3.5 billion to shareholders. The CEO expressed confidence in the company's future. Annual guidance for 2024 forecasts revenue of $42.1 billion to $43.3 billion and adjusted EPS of $20.95 to $22.00.
linkJan 31, 2024 06:02:33
Thermo Fisher Scientific Inc. has issued a notice to directors and executive officers regarding a blackout period and trading restrictions due to a suspension of transactions in the company's 401(k) plan. The blackout period is necessary for the transition to a new administrator and is expected to begin on December 21, 2023, and end during the week of January 14, 2024. During this period, directors and executive officers are prohibited from purchasing, selling, or transferring any common stock, including derivatives, acquired in connection with their service. Violations may result in disgorgement of profits and civil and criminal penalties.
linkNov 07, 2023 16:15:57
Thermo Fisher Scientific reported its financial results for the third quarter of 2023, with revenue of $10.57 billion, a 1% decrease compared to the same quarter last year. However, the company saw an increase in diluted earnings per share (EPS) and adjusted EPS. Thermo Fisher Scientific also announced an agreement to acquire Olink Holding AB for approximately $3.1 billion and highlighted its collaboration with the National Minority Quality Forum to increase diversity in clinical trials. Despite market conditions, the company remains focused on delivering short-term performance while enhancing its long-term competitive position.
linkOct 25, 2023 06:03:22